Trevi Therapeutics Inc., a clinical-stage biopharmaceutical company, has announced the pricing of its underwritten public offering, issuing 17,400,000 shares of common stock at a price of $5.75 per share, aiming to raise $100 million. The offering proceeds are before the deduction of underwriting discounts, commissions, and expenses. Trevi has also provided underwriters with a 30-day option to purchase an additional 2,610,000 shares at the same price. The offering, managed by Morgan Stanley, Leerink Partners, Stifel, and Cantor, is expected to close on or around June 5, 2025, pending customary closing conditions. The funds will support Trevi's ongoing development of Haduvio™, an investigational therapy for chronic cough associated with idiopathic pulmonary fibrosis and refractory chronic cough.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.